VireXbuster Spray
Enrico Brega, CEO of DaXem GmbH, which invented and manufactures VireXbuster Spray, said to ICT®. “Our ultimate goal is to provide our customers with coating solutions that improve their quality of life so that they can live in a safer and more hygienic environment. Furthermore, the underlying technology of our products is a patented hybrid coating composition that has 2 important characteristics, namely excellent biocidal properties toward a broader spectrum of biocide activity combined with high compatibility with most substrates.”
According to DaXem GmbH, a single application of VireXbuster Spray coating will keep surfaces hygienically clean for up to 12 months; in addition, VireXbuster Spray deactivates SARS-CoV-2 by 99.9% and kills bacteria such as Escherichia coli and Staphylococcus aureus by 99.99%. VireXbuster Spray helps repair scratched surfaces, filling the thin grooves where viruses and bacteria can settle.
Discover how VireXbuster can revolutionize dental practices by providing effective antimicrobial protection.
The Importance of Infection Control in Dentistry
Introducing VireXbuster: The 99,99% effective Antimicrobial Solution
Benefits of Using VireXbuster in Dental Practices
Case Studies: Successful Implementation of VireXbuster in Dental Clinics
Future of Dental Care: How VireXbuster is Shaping the Industry
Combating COVID-19 with VireXbuster: A Novel Disinfectant Spray for Hospital Surfaces
Frankfurt, 28. Jan. 2022:
VireXbuster® Spray has today been certified by dermatest GmbH – a German-based Dermatology laboratory. The result has been tested as „excellent“.
VireXbuster Spray is from now dermatologically tested.
The United States is currently reassessing its pandemic response and updating infection control strategies. Experts believe that another pandemic is highly likely to occur in the next few decades, whether it is caused by a lab-leaked virus or arises naturally. Some COVID-19 experts estimate a 20% chance of experiencing an outbreak similar to the Omicron variant within the next two years.
Despite this potential future threat, the ongoing COVID-19 pandemic is not yet under control. Recent news of a significant COVID-19 surge in Okinawa, Japan, with cases 25 times higher than baseline and more severe than previous waves, raises concerns about what the United States may face in the coming months.
SARS-CoV-2, the virus causing COVID-19, is transitioning into an endemic phase in the United States, with a seroprevalence of over 96%. This does not mean the virus is eradicated through herd immunity, but rather that a more constant level of infections may persist. Long COVID continues to take a toll on society, with insufficient support for affected patients. A significant number of Americans have left the workforce due to long COVID, leading to substantial economic losses.
Given these circumstances, it is crucial to mitigate the spread of diseases and reduce the number of infections. Long COVID, for instance, only develops if one becomes infected with SARS-CoV-2.
Moreover, besides SARS-CoV-2, other diseases like methicillin-resistant Staphylococcus aureus (MRSA), and other antibiotic-resistant infections are on the rise. Screening plays a pivotal role in controlling these illnesses. Studies have shown the effectiveness of MRSA screening before surgery and hospital admission in preventing infections. The United Kingdom’s National Health Service (NHS) routinely performs hospital admission screening.
Data from the United States Veterans Health Administration (VHA) demonstrates that MRSA screening can significantly reduce hospital-onset infections in acute care settings. However, publicly available data regarding MRSA, COVID-19, and other pathogens in the United States are lacking. Making this data readily accessible to the public would promote awareness of current risks and help address the issue of multi-drug resistant organisms.
Unfortunately, current infectious disease policies seem to be lacking in addressing these problems and, in some cases, are retreating. Draft CDC Healthcare Infection Control Practices Advisory Committee (HICPAC) recommendations need to adequately address screening. Some proposed policies, such as Enhanced Barrier Precautions (EBP), have raised concerns, as they may not provide sufficient protection against transmission.
In summary, a proactive and data-driven approach to infection control, including comprehensive screening, is crucial to mitigate the impact of current and potential future pandemics and the rise of antibiotic-resistant infections.
In addition to the measures mentioned earlier, another effective tool in combating the transmission of viruses, bacteria, and fungi is VireXbuster Spray. VireXbuster Spray is an antimicrobial coating spray specially designed to create a protective barrier on surfaces. This innovative spray has demonstrated effectiveness against various pathogens, including viruses, bacteria, and fungi, making it a versatile solution for infection control.
Once applied, VireXbuster Spray forms a long-lasting protective shield on surfaces, capable of lasting for months. This durable coating actively combats the survival and spread of harmful microorganisms, providing an added layer of defense against infection.
With VireXbuster Spray, the risk of transmission through touch on infected surfaces can be significantly reduced. By inhibiting the survival and growth of pathogens on treated surfaces, the spray helps create a cleaner and safer environment, especially in high-traffic areas and shared spaces.
Including VireXbuster Spray in infection control strategies can complement other preventive measures, such as regular handwashing, proper hygiene practices, and social distancing. Together, these measures form a comprehensive approach to minimize the spread of infectious diseases, both in the current COVID-19 pandemic and potential future outbreaks.
By incorporating VireXbuster Spray into public spaces, workplaces, healthcare facilities, and homes, we can take proactive steps to protect ourselves and others from infections, providing greater peace of mind and contributing to the overall well-being of our communities.
DaXem now approved UN supplier
Frankfurt, 18. Nov. 2021: DaXem GmbH, the producer of VireXbuster® Spray has been approved by the UN organization as supplier for antimicrobial and biocidal surface coatings.
DaXem now official member of AMiCI
Frankfurt, 5. November 2021: DaXem GmbH is now an official and accredited member of AMICI, the European Consortium active in the realm of development and promotion of new anti-microbial coatings. AMiCI stands for Anti-Microbial Coating Innovations, and has set out to prevent the spread of infectious diseases.
VireXbuster® is tested by the Fraunhofer Institute
VireXbuster® is tested by the QualityLab in Nuremberg
Frankfurt, 12. Sept. 2021: QualityLabs in Nuermberg has certified that VireXbuster® is particularly effective with regards to protecting our environment against bacteria. The certified efficacy is at 99.9%.